Stimuli-responsive therapeutic metallodrugs
The success of platinum-based anticancer agents has motivated the exploration of novel
metal-based drugs for several decades, whereas problems such as drug-resistance and …
metal-based drugs for several decades, whereas problems such as drug-resistance and …
Current development of metal complexes with diamine ligands as potential anticancer agents
S Misirlic-Dencic, J Poljarevic… - Current Medicinal …, 2020 - benthamdirect.com
Background: The discovery of cisplatin and the subsequent research revealed the
importance of dinitrogen-containing moiety for the anticancer action of metal complexes …
importance of dinitrogen-containing moiety for the anticancer action of metal complexes …
Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models
Using platinum (iv) prodrugs of clinically established platinum (ii) compounds is a strategy to
overcome side effects and acquired resistances. We studied four oxaliplatin-derived …
overcome side effects and acquired resistances. We studied four oxaliplatin-derived …
Oxidative stress induced by Pt (IV) pro-drugs based on the cisplatin scaffold and indole carboxylic acids in axial position
The use of Pt (IV) complexes as pro-drugs that are activated by intracellular reduction is a
widely investigated approach to overcome the limitations of Pt (II) anticancer agents. A …
widely investigated approach to overcome the limitations of Pt (II) anticancer agents. A …
Synthesis, structural characterization and cell death-inducing effect of novel palladium (II) and platinum (II) saccharinate complexes with 2-(hydroxymethyl) pyridine …
Four palladium (II) and platinum (II) saccharinate (sac) complexes with 2-(hydroxymethyl)
pyridine (2-hmpy) and 2-(2-hydroxyethyl) pyridine (2-hepy), namely trans-[Pd (2-hmpy) 2 …
pyridine (2-hmpy) and 2-(2-hydroxyethyl) pyridine (2-hepy), namely trans-[Pd (2-hmpy) 2 …
The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum (IV) prodrugs
The current study aims to elucidate the possible reasons for the significantly different
pharmacological behavior of platinum (IV) complexes with cisplatin-, carboplatin-or …
pharmacological behavior of platinum (IV) complexes with cisplatin-, carboplatin-or …
Evaluation of functionalized mesoporous silica SBA-15 as a carrier system for Ph 3 Sn (CH 2) 3 OH against the A2780 ovarian carcinoma cell line
SBA-15| Sn3, a mesoporous silica-based material (derivative of SBA-15) loaded with an
organotin compound Ph3Sn (CH2) 3OH (Sn3), possesses improved antitumor potential …
organotin compound Ph3Sn (CH2) 3OH (Sn3), possesses improved antitumor potential …
Influence of reducing agents on the cytotoxic activity of platinum(iv) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin …
V Pichler, S Göschl, E Schreiber-Brynzak… - Metallomics, 2015 - academic.oup.com
The concept of PtIV prodrug design is one advanced strategy to increase the selectivity for
cancer cells and to reduce systemic toxicity in comparison to established platinum-based …
cancer cells and to reduce systemic toxicity in comparison to established platinum-based …
In vitro anticancer activity of gold (III) complexes with some esters of (S, S)-ethylenediamine-N, N′-di-2-propanoic acid
N Pantelić, TP Stanojković, BB Zmejkovski… - European Journal of …, 2015 - Elsevier
Five novel gold (III) complexes of general formulas [AuCl 2 {(S, S)-R 2 eddip}] PF 6,((S, S)-
eddip=(S, S)-ethylenediamine-N, N′-di-2-propanoate, R= n-Bu, n-Pe, i-Bu, i-Am, cPe; 1–5 …
eddip=(S, S)-ethylenediamine-N, N′-di-2-propanoate, R= n-Bu, n-Pe, i-Bu, i-Am, cPe; 1–5 …
[HTML][HTML] Pt (IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance …
Epigenetic agents such as histone deacetylase (HDAC) inhibitors are widely investigated for
use in combined anticancer therapy and the co-administration of Pt drugs with HDAC …
use in combined anticancer therapy and the co-administration of Pt drugs with HDAC …